最新！肝がん・胆道がんの薬物療法・第28回がんチューブ専門医ダイレクトライブ20260419

Value of the Information & Strength of the Argument

The video provides substantial value by offering an up-to-date overview of treatment options for liver and biliary cancers, directly from a leading expert. The argumentation is solid, grounded in clinical experience and references to recent studies, such as the IMbrave150 and HIMALAYA trials. The discussion of MASLD as an emerging risk factor is particularly valuable, as it highlights a shift in disease etiology and prevention strategies. The expert’s explanations are clear and supported by clinical data, though some claims, such as the influence of administration time on immunotherapy efficacy, are based on retrospective analyses and should be interpreted with caution.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with the speaker citing major clinical trials and guidelines. The quality of sources is good, as the speaker is a recognized authority in the field. The title accurately reflects the content, which focuses on the latest drug therapies. The video includes a Q&A segment where the expert addresses patient concerns, adding practical value. However, the lack of explicit citations or links to specific studies in the description limits the verifiability of some claims. The title is appropriate and does not overstate the content.

The title accurately reflects the content, which focuses on the latest drug therapies for liver and biliary tract cancers.

8/10

The video features a leading expert in hepatobiliary oncology from a national cancer center, presenting current treatment standards and recent advances. The content aligns with established medical knowledge, though it is primarily an expert opinion and educational discussion rather than a peer-reviewed presentation.

• 00:00オープニング・出演者紹介（沖英次先生、池田公史先生、青木みちひとさん）
• 05:51基調講演：最新の肝がん・胆道がん薬物療法（講師：池田公史先生）
• 06:56肝胆膵がん治療の変遷：絶望の時代から希望の時代へ
• 11:35肝がんの基礎知識：原発性と転移性の違い
• 12:39肝細胞がんの背景：C型肝炎の減少と生活習慣病の台頭
• 14:04新しい疾患概念「MASLD（マッスルド）」：代謝異常関連の脂肪性肝疾患
• 20:18肝細胞がんの治療アルゴリズム：切除、ラジオ波、塞栓術、薬物療法の使い分け
• 21:25肝細胞がんの薬物療法：免疫チェックポイント阻害剤による革新
• 28:11胆道がん（肝内・肝外・胆嚢）の最新薬物療法と併用療法
• 29:53ゲノム医療による個別化医療：FGFR2やHER2を標的とした治療法
• 31:45免疫療法の効果を高めるヒント：投与時間（午前中）とワクチンの関係
• 35:30質疑応答：ラジオ波焼灼術の仕組みとマイクロ波の違い
• 38:04質疑応答：糖尿病などの基礎疾患がある場合のがん治療
• 40:18質疑応答：高齢者（90歳代）の全身状態の評価と治療適応
• 45:51専門解説：脂肪肝のメカニズムとフォアグラ状態の正体
• 53:15質疑応答：肝内胆管がんステージ4Bで長期生存するためのヒント
• 56:35質疑応答：進行・再発子宮頸がんの標準治療と家族にできること
• 1:02:15質疑応答：乳がんホルモン療法中の脂肪肝への向き合い方
• 1:07:40専門解説：CT画像で原発性肝がんと大腸がん肝転移を見分ける方法
• 1:14:30質疑応答：腫瘍マーカー（AFP、PIVKA-II）の正しい捉え方
• 1:21:20質疑応答：乳がん肝転移での余命宣告と前向きに生きるための筋トレ
• 1:27:00質疑応答：膵がん術後の体重減少と消化酵素薬（リパクレオン）の活用
• 1:31:15質疑応答：遺伝子パネル検査における日本版と米国版の選択基準
• 1:38:10質疑応答：89歳の膵がん再発疑い、粒子線治療か抗がん剤か
• 1:43:55質疑応答：胆道がんのステント閉塞と肺塞栓症（血栓）への対応
• 1:52:35質疑応答：がん悪液質の治療薬（エドルミズ）と高カロリー輸液の考え方
• 2:08:45エンディング・本日のまとめ

• MASLD Clinical Practice Guidelines 2026 — Mentioned as recently published guidelines for the new disease concept MASLD.
• IMbrave150 trial — Referenced as the basis for atezolizumab plus bevacizumab in hepatocellular carcinoma.
• HIMALAYA trial — Referenced for durvalumab plus tremelimumab combination.
• CheckMate 9DW trial — Referenced for nivolumab plus ipilimumab combination.
• TOPAZ-1 trial — Referenced for durvalumab plus gemcitabine-cisplatin in biliary tract cancer.
• KEYNOTE-966 trial — Referenced for pembrolizumab plus gemcitabine-cisplatin in biliary tract cancer.

• IMbrave150 trial — Supports the efficacy of atezolizumab plus bevacizumab in HCC.
• HIMALAYA trial — Supports durvalumab plus tremelimumab in HCC.
• TOPAZ-1 trial — Supports durvalumab plus gemcitabine-cisplatin in biliary tract cancer.